S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund's adjuvant models in mice

Behavioural Pharmacology

Volumn 25, Issue 3, 2014, Pages 226-235

  Gris, Georgia ^a   Merlos, Manuel ^a   Vela, José M ^a   Zamanillo, Daniel ^a   Portillo Salido, Enrique ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

allodynia; carrageenan; complete Freund's adjuvant; E 52862; hyperalgesia; hypersensitivity; inflammatory pain; r1R knockout mouse; S1RA; sigma 1 receptor

Indexed keywords

CARRAGEENAN; CELECOXIB; E 52862; FREUND ADJUVANT; IBUPROFEN; MORPHINE; OPIATE ANTAGONIST; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; 4-(2-((5-METHYL-1-(2-NAPHTHALENYL)-1H-PYRAZOL-3-YL)OXY)ETHYL)MORPHOLINE; MORPHOLINE DERIVATIVE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HYPERALGESIA; HYPERSENSITIVITY; INFLAMMATORY PAIN; MOUSE; NONHUMAN; PAW EDEMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DISEASE MODEL; EDEMA; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; MALE; PAIN; PAIN MEASUREMENT; TIME; TOXICITY;

ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; DISEASE MODELS, ANIMAL; EDEMA; FREUND'S ADJUVANT; HYPERALGESIA; IBUPROFEN; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; MORPHINE; MORPHOLINES; PAIN; PAIN MEASUREMENT; PYRAZOLES; RECEPTORS, SIGMA; TIME FACTORS;

EID: 84899831063     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000038     Document Type: Article

References (51)

1. Abadias M, Escriche M, Vaqué A, Sust M, Encina G (2013). Safety, tolerabilityand pharmacokinetics of single and multiple doses of a novel sigma-1receptor antagonist in three randomized phase I studies. Br J Clin Pharmacol75:103-117.
2. Almarestani L, Fitzcharles MA, Bennett GJ, Ribeiro-da-Silva A (2011). Imagingstudies in Freund's complete adjuvant model of regional polyarthritis, a modelsuitable for the study of pain mechanisms, in the rat. Arthritis Rheum63:1573-1581.
3. Bellavance LL, Beitz AJ (1996). Altered c-fos expression in the parabrachialnucleus in a rodent model of CFA-induced peripheral inflammation. J CompNeurol 366:431-447.
4. Bendele A (2001). Animal models of rheumatoid arthritis. J MusculoskeletNeuronal Interact 1:377-385.
5. Bennet AD, Everhart AW, Hulsebosch CE (2000). Intrathecal administration of anNMDA or a non-NMDA receptor antagonist reduces mechanical but notthermal allodynia in a rodent model of chronic central pain after spinal cordinjury. Brain Res 859:72-82.
6. Bileviciute-Ljungar I, Spetea M, Guo Y, Schü tz J, Windisch P, Schmidhammer H(2006). Peripherally mediated antinociception of the mu-opioid receptoragonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan- 6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administrationin rats with carrageenan-induced hindpaw inflammation. J PharmacolExp Ther 317:220-227.
7. Casarrubea M, Sorbera F, Santangelo A, Crescimanno G (2011). Learninginfluence on the behavioral structure of rat response to pain in hot-plate.Behav Brain Res 225:177-183.
8. Cendán CM, Pujalte JM, Portillo-Salido E, Montoliu L, Baeyens JM (2005).Formalin-induced pain is reduced in sigma(1) receptor knockout mice. Eur JPharmacol 511:73-74.
9. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitativeassessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
10. Cobos EJ, Portillo-Salido E (2013). "Bedside-to-bench" behavioral outcomes inanimal models of pain: beyond the evaluation of reflexes. Curr Neuropharmacol11:560-591.
11. Cobos EJ, Baeyens JM, Del Pozo E (2005). Phenytoin differentially modulates theaffinity of agonist and antagonist ligands for sigma 1 receptors of guineapig brain. Synapse 55:192-195.
12. Cobos EJ, Ghasemlou N, Araldi D, Segal D, Duong K, Woolf CJ (2012).Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexivetest for evaluating inflammatory pain and analgesia. Pain 153:876-884.
13. De la Puente B, Nadal X, Portillo-Salido E, Sánchez-Arroyos R, Ovalle S, Palacios G,et al. (2009). Sigma-1 receptors regulate activity-induced spinal sensitization andneuropathic pain after peripheral nerve injury. Pain 145:294-303.
14. Dijkmans BA, Janssen M, Vandenbroucke JP, Lamers CB (1995). NSAIDassociatedupper gastrointestinal damage in patients with rheumatoidarthritis. Scand J Gastroenterol Suppl 212:105-108.
15. Dixon WJ (1980). Efficient analysis of experimental observations. Annu RevPharmacol Toxicol 20:441-462.
16. Dowdall T, Robinson I, Meert TF (2005). Comparison of five different rat modelsof peripheral nerve injury. Pharmacol Biochem Behav 80:93-108.
17. Drews E, Zimmer A (2009). Central sensitization needs sigma receptors. Pain145:269-270.
18. Entrena JM, Cobos EJ, Nieto FR, Cendán CM, Gris G, Del Pozo E, et al. (2009).Sigma-1 receptors are essential for capsaicin-induced mechanical hypersensitivity:studies with selective sigma-1 ligands and sigma-1 knockout mice.Pain 143:252-261.
19. Gó mez-Soler M, Fernández-Dueñ as V, Portillo-Salido E, Pé rez P, Zamanillo D,Vela JM, et al. (2014). Predicting the antinociceptive efficacy of s(1) receptorligands by a novel receptor fluorescence resonance energy transfer (FRET)based biosensor. J Med Chem 57:238-242.
20. González-Cano R, Merlos M, Baeyens JM, Cendán CM (2013). s1 receptors areinvolved in the visceral pain induced by intracolonic administration ofcapsaicin in mice. Anesthesiology 118:691-700.
21. Gould HJ 3rd, England JD, Soignier RD, Nolan P, Minor LD, Liu ZP, et al. (2004).Ibuprofen blocks changes in Na v 1.7 and 1.8 sodium channels associated withcomplete Freund's adjuvant-induced inflammation in rat. J Pain 5:270-280.
22. Hargreaves K, Dubner R, Brown F, Flores C, Joris J 1988. A new and sensitive methodfor measuring thermal nociception in cutaneous hyperalgesia. Pain 32;77-88
23. Lähdesmä ki J, Scheinin M, Pertovaara A, Mansikka H (2003). The alpha2Aadrenoceptorsubtype is not involved in inflammatory hyperalgesia ormorphine-induced antinociception. Eur J Pharmacol 468:183-189.
24. Langa F, Codony X, Tovar V, Lavado A, Giménez E, Cozar P, et al. (2003).Generation and phenotypic analysis of sigma receptor type I (sigma 1)knockout mice. Eur J Neurosci 18:2188-2196.
25. Lee BH, Yoon YW, Chung K, Chung JM (1998). Comparison of sympatheticsprouting in sensory ganglia in three animal models of neuropathic pain. ExpBrain Res 120:432-438.
26. Li K, Tan YH, Light AR, Fu KY (2013). Different peripheral tissue injury inducesdifferential phenotypic changes of spinal activated microglia. Clin DevImmunol 2013:901420.
27. Liang DY, Guo T, Liao G, Kingery WS, Peltz G, Clark JD (2006). Chronic pain andgenetic background interact and influence opioid analgesia, tolerance, andphysical dependence. Pain 121:232-240.
28. Luger NM, SabinoMA, Schwei MJ,Mach DB, Pomonis JD, Keyser CP, et al. (2002).Efficacy of systemic morphine suggests a fundamental difference in themechanisms that generate bone cancer vs inflammatory pain. Pain 99:397-406.
29. Mansikka H, Sheth RN, DeVries C, Lee H,Winchurch R, Raja SN (2000). Nerveinjury-induced mechanical but not thermal hyperalgesia is attenuated inneurokinin-1 receptor knockout mice. Exp Neurol 162:343-349.
30. Molina C, Herrero JF (2006). The influence of the time course of inflammation andspinalization on the antinociceptive activity of the alpha2-adrenoceptoragonist medetomidine. Eur J Pharmacol 532:50-60.]
31. Nahas RI, Lever JR, Lever SZ (2008). Synthesis and structure-activity relationshipsof N-(3-phenylpropyl)-N'-benzylpiperazines: potent ligands for sigma1and sigma2 receptors. Bioorg Med Chem 16:755-761.
32. Nieto FR, Cendán CM, Sánchez-Fernández C, Cobos EJ, Entrena JM, Tejada MA,et al. (2012). Role of sigma-1 receptors in paclitaxel-induced neuropathicpain in mice. J Pain 13:1107-1121.
33. Ortiz MI, Ponce-Monter H, Fernández-Mart?́nez E, Pé rez-Hernández N, Mac?́as A,Rangel-Flores E, Castañ eda-Hernández G (2007). Evaluation of theinteraction between acemetacin and opioids on the hargreaves model ofthermal hyperalgesia. Pharmacol Biochem Behav 88:47-54.
34. Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, et al. (2007). Arole of TRPA1 in mechanical hyperalgesia is revealed by pharmacologicalinhibition. Mol Pain 3:40.
35. Pisetsky DS, Ward MM (2012). Advances in the treatment of inflammatoryarthritis. Best Pract Res Clin Rheumatol 26:251-261.
36. Radner H, Ramiro S, Buchbinder R, Landewé RB, van der Heijde D, Aletaha D(2012). Pain management for inflammatory arthritis (rheumatoid arthritis, psoriaticarthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal orliver comorbidity. Cochrane Database Syst Rev 1:CD008951.
37. Rahn EJ, Guzman-Karlsson MC, David Sweatt J (2013). Cellular, molecular, andepigenetic mechanisms in non-associative conditioning: Implications for painand memory. Neurobiol Learn Mem 105:133-150.
38. Romero L, Zamanillo D, Nadal X, Sánchez-Arroyos R, Rivera-Arconada I, Dordal A,et al. (2012). Pharmacological properties of S1RA, a new sigma-1 receptorantagonist that inhibits neuropathic pain and activity-induced spinal sensitization.Br J Pharmacol 166:2289-2306.
39. Rutten K, De Vry J, Robens A, Tzschentke TM, van der Kam EL (2011).Dissociation of rewarding, anti-aversive and anti-nociceptive effects ofdifferent classes of anti-nociceptives in the rat. Eur J Pain 15:299-305.
40. Sammons MJ, Raval P, Davey PT, Rogers D, Parsons AA, Bingham S (2000).Carrageenan-induced thermal hyperalgesia in the mouse: role of nervegrowth factor and the mitogen-activated protein kinase pathway. Brain Res876:48-54.
41. Schepers RJ, Mahoney JL, Gehrke BJ, Shippenberg TS (2008). Endogenouskappa-opioid receptor systems inhibit hyperalgesia associated with localizedperipheral inflammation. Pain 138:423-439.
42. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE (2010). The sigma-1 receptorchaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci31:557-566.
43. Van Laar M, Pergolizzi JV Jr, Mellinghoff HU, Merchante IM, Nalamachu S, O'Brien J,et al. (2012). Pain treatment in arthritis-related pain: beyond NSAIDs. OpenRheumatol J 6:320-330.
44. Vidal-Torres A, de la Puente B, Rocasalbas M, Touriño C, Andreea Bura S,Ferná ndez-Pastor B, et al. (2013). Sigma-1 receptor antagonism as opioidadjuvant strategy: enhancement of opioid antinociception without increasingadverse effects. Eur J Pharmacol 711:63-72.
45. Walsh DA, McWilliams DF (2012). Pain in rheumatoid arthritis. Curr PainHeadache Rep 16:509-517.
46. Whittle SL, Richards BL, Buchbinder R (2013). Opioid analgesics for rheumatoidarthritis pain. JAMA 309:485-486.
47. Wong GT (2002). Speed congenics: applications for transgenic and knock-outmouse strains. Neuropeptides 36:230-236.
48. Woolf CJ (2011). Central sensitization: implications for the diagnosis andtreatment of pain. Pain 152:S2-S15.
49. Zamanillo D, Portillo-Salido E, Vela JM, Romero L (2012). Sigma 1 receptorchaperone: pharmacology and therapeutic perspectives. In: Botana M, Loza M,editors. Therapeutic targets: modulation, inhibition, and activation. Hoboken,NJ, USA: John Wiley & Sons Inc. pp. 225-278.
50. Zamanillo D, Romero L, Merlos M, Vela JM (2013). Sigma 1 receptor: A newtherapeutic target for pain. Eur J Pharmacol 716:78-93.
51. Zimmermann M (1983). Ethical guidelines for investigations of experimental painin conscious animals. Pain 16:109-110.